Product Details
Place of Origin: China
Brand Name: Quickoolchem
Payment & Shipping Terms
Minimum Order Quantity: 50 grams
Price: Negotiable
Packaging Details: 1kg/Bag; 25kg/Carton
Delivery Time: 2-3 days
Payment Terms: T/T, Western Union, MoneyGram
Supply Ability: 10 MT/Month
Synonyms: |
EIDD-2801; MK-4482; Molnupiravir Prodrug |
Density: |
1.46 G/cm3 |
Purity: |
≥99% |
Solubility: |
Soluble In DMSO And Methanol |
Refractive Index: |
1.617 |
Molecular Formula: |
C13H19N3O7 |
Boiling Point: |
~600.3°C At 760 MmHg |
Flash Point: |
316.5°C |
Package: |
1kg/bag, 25kg/drum |
Origin: |
China |
Synonyms: |
EIDD-2801; MK-4482; Molnupiravir Prodrug |
Density: |
1.46 G/cm3 |
Purity: |
≥99% |
Solubility: |
Soluble In DMSO And Methanol |
Refractive Index: |
1.617 |
Molecular Formula: |
C13H19N3O7 |
Boiling Point: |
~600.3°C At 760 MmHg |
Flash Point: |
316.5°C |
Package: |
1kg/bag, 25kg/drum |
Origin: |
China |
Molnupiravir, also known as EIDD-2801, is an antiviral drug that gained attention during the COVID-19 pandemic. It was developed by Emory University and Ridgeback Biotherapeutics. Molnupiravir works by introducing errors into the genetic material of the virus, hindering its ability to replicate properly. It was originally developed for the treatment of influenza but has shown promise against other viruses as well, including coronaviruses.
Molnupiravir is a prodrug, meaning it is metabolized into its active form in the body. Its chemical structure includes a nucleoside analog backbone, which is similar to the building blocks of RNA. This structural similarity allows Molnupiravir to interfere with the replication process of RNA viruses.
| Parameter | Value |
|---|---|
| Boiling Point | ~600.3°C At 760 MmHg |
| Cas Number | 2349386-89-4 |
| Synonyms | EIDD-2801; MK-4482; Molnupiravir Prodrug |
| Flash Point | 316.5°C |
| Solubility | Soluble In DMSO And Methanol |
| Refractive Index | 1.617 |
| Storage | Store At -20°C |
| Purity | ≥99% |
| Appearance | White To Off-white Powder |
COVID-19 Treatment: One of the most significant applications of molnupiravir is in the treatment of COVID-19. Clinical trials have indicated that it can reduce the duration of symptoms and decrease the risk of hospitalization in patients with mild to moderate COVID-19. If approved by regulatory agencies, it could become an essential tool in managing the pandemic.
Antiviral Therapy: Molnupiravir's mechanism of action involves inducing errors in the genetic material of the virus, inhibiting its replication. This broad-spectrum antiviral activity suggests potential applications beyond COVID-19, including other viral infections such as influenza and respiratory syncytial virus (RSV).
Preventive Treatment: There is ongoing research into the use of molnupiravir as a preventive measure against viral infections. If proven effective, it could be used prophylactically in high-risk populations or during outbreaks to limit the spread of viral diseases.
Animal Health: Molnupiravir might also find applications in veterinary medicine for treating viral infections in animals. This could be particularly relevant for diseases that affect livestock or companion animals.
1~25kgs packaging: Aluminium bag inside, Carton box outside.
25kgs packaging: Plastic bag inside, Fiber drum outside
